115 related articles for article (PubMed ID: 21798616)
21. GPR109A and vascular inflammation.
Chai JT; Digby JE; Choudhury RP
Curr Atheroscler Rep; 2013 May; 15(5):325. PubMed ID: 23526298
[TBL] [Abstract][Full Text] [Related]
22. Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis.
Ingersoll MA; Potteaux S; Alvarez D; Hutchison SB; van Rooijen N; Randolph GJ
Immunobiology; 2012 May; 217(5):548-57. PubMed ID: 21798616
[TBL] [Abstract][Full Text] [Related]
23. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.
Benyó Z; Gille A; Kero J; Csiky M; Suchánková MC; Nüsing RM; Moers A; Pfeffer K; Offermanns S
J Clin Invest; 2005 Dec; 115(12):3634-40. PubMed ID: 16322797
[TBL] [Abstract][Full Text] [Related]
24. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
Kamanna VS; Kashyap ML
Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
[TBL] [Abstract][Full Text] [Related]
25. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
Lauring B; Taggart AK; Tata JR; Dunbar R; Caro L; Cheng K; Chin J; Colletti SL; Cote J; Khalilieh S; Liu J; Luo WL; Maclean AA; Peterson LB; Polis AB; Sirah W; Wu TJ; Liu X; Jin L; Wu K; Boatman PD; Semple G; Behan DP; Connolly DT; Lai E; Wagner JA; Wright SD; Cuffie C; Mitchel YB; Rader DJ; Paolini JF; Waters MG; Plump A
Sci Transl Med; 2012 Aug; 4(148):148ra115. PubMed ID: 22914621
[TBL] [Abstract][Full Text] [Related]
26. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential.
Gaidarov I; Chen X; Anthony T; Maciejewski-Lenoir D; Liaw C; Unett DJ
Cell Signal; 2013 Oct; 25(10):2003-16. PubMed ID: 23770183
[TBL] [Abstract][Full Text] [Related]
27. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression.
Potteaux S; Gautier EL; Hutchison SB; van Rooijen N; Rader DJ; Thomas MJ; Sorci-Thomas MG; Randolph GJ
J Clin Invest; 2011 May; 121(5):2025-36. PubMed ID: 21505265
[TBL] [Abstract][Full Text] [Related]
28. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.
Lukasova M; Malaval C; Gille A; Kero J; Offermanns S
J Clin Invest; 2011 Mar; 121(3):1163-73. PubMed ID: 21317532
[TBL] [Abstract][Full Text] [Related]
29. LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression.
Feig JE; Pineda-Torra I; Sanson M; Bradley MN; Vengrenyuk Y; Bogunovic D; Gautier EL; Rubinstein D; Hong C; Liu J; Wu C; van Rooijen N; Bhardwaj N; Garabedian M; Tontonoz P; Fisher EA
J Clin Invest; 2010 Dec; 120(12):4415-24. PubMed ID: 21041949
[TBL] [Abstract][Full Text] [Related]
30. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses.
Paust S; Gill HS; Wang BZ; Flynn MP; Moseman EA; Senman B; Szczepanik M; Telenti A; Askenase PW; Compans RW; von Andrian UH
Nat Immunol; 2010 Dec; 11(12):1127-35. PubMed ID: 20972432
[TBL] [Abstract][Full Text] [Related]
31. New evidence for nicotinic acid treatment to reduce atherosclerosis.
Montecucco F; Quercioli A; Dallegri F; Viviani GL; Mach F
Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1457-67. PubMed ID: 20936932
[TBL] [Abstract][Full Text] [Related]
32. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice.
Hanson J; Gille A; Zwykiel S; Lukasova M; Clausen BE; Ahmed K; Tunaru S; Wirth A; Offermanns S
J Clin Invest; 2010 Aug; 120(8):2910-9. PubMed ID: 20664170
[TBL] [Abstract][Full Text] [Related]
33. Seeing red: flushing out instigators of niacin-associated skin toxicity.
Dunbar RL; Gelfand JM
J Clin Invest; 2010 Aug; 120(8):2651-5. PubMed ID: 20664168
[TBL] [Abstract][Full Text] [Related]
34. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids.
Wu BJ; Yan L; Charlton F; Witting P; Barter PJ; Rye KA
Arterioscler Thromb Vasc Biol; 2010 May; 30(5):968-75. PubMed ID: 20167660
[TBL] [Abstract][Full Text] [Related]
35. Extended-release niacin or ezetimibe and carotid intima-media thickness.
Taylor AJ; Villines TC; Stanek EJ; Devine PJ; Griffen L; Miller M; Weissman NJ; Turco M
N Engl J Med; 2009 Nov; 361(22):2113-22. PubMed ID: 19915217
[TBL] [Abstract][Full Text] [Related]
36. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study.
Lee JM; Robson MD; Yu LM; Shirodaria CC; Cunnington C; Kylintireas I; Digby JE; Bannister T; Handa A; Wiesmann F; Durrington PN; Channon KM; Neubauer S; Choudhury RP
J Am Coll Cardiol; 2009 Nov; 54(19):1787-94. PubMed ID: 19874992
[TBL] [Abstract][Full Text] [Related]
37. Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin.
Digby JE; McNeill E; Dyar OJ; Lam V; Greaves DR; Choudhury RP
Atherosclerosis; 2010 Mar; 209(1):89-95. PubMed ID: 19781706
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
